Functional status in older patients with cancer
Anne‐Laure Couderc(Centre National de la Recherche Scientifique), P. Villani(Centre National de la Recherche Scientifique), Aurélie Daumas(Inserm), Sébastien Salas(Assistance Publique Hôpitaux de Marseille), Laurent Greillier(Aix-Marseille Université), Robin Arcani(Inserm), Florence Duffaud(Aix-Marseille Université), Anaïs Courcier(Assistance Publique Hôpitaux de Marseille), Laure Farnault(Aix-Marseille Université), Régis Costello(Inserm), Geoffroy Venton(Inserm), Emilie Nouguerède(Hôpital Sainte-Marguerite), Fabrice Barlési(Hôpital Nord), Pierre Suchon(Inserm), Bérengère Saliba‐Serre(Centre National de la Recherche Scientifique), Dominique Rey(Hôpital Sainte-Marguerite)
Cited by 9
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
|The Lancet Respiratory Medicine|2019|937
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766